eFFECTOR Therapeutics, Inc.

OTCPK:EFTR Stock Report

Market Cap: US$229.3k

eFFECTOR Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

eFFECTOR Therapeutics has a total shareholder equity of $827.0K and total debt of $20.0M, which brings its debt-to-equity ratio to 2420.3%. Its total assets and total liabilities are $27.1M and $26.3M respectively.

Key information

2,420.3%

Debt to equity ratio

US$20.02m

Debt

Interest coverage ration/a
CashUS$25.38m
EquityUS$827.00k
Total liabilitiesUS$26.30m
Total assetsUS$27.13m

Recent financial health updates

Recent updates

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Sep 14

eFFECTOR Therapeutics GAAP EPS of -$0.17

Aug 09

eFFECTOR: Developing New Class Of Cancer Therapies

Sep 12

Financial Position Analysis

Short Term Liabilities: EFTR's short term assets ($26.3M) exceed its short term liabilities ($25.6M).

Long Term Liabilities: EFTR's short term assets ($26.3M) exceed its long term liabilities ($735.0K).


Debt to Equity History and Analysis

Debt Level: EFTR has more cash than its total debt.

Reducing Debt: Insufficient data to determine if EFTR's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EFTR has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: EFTR is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies